IRVINE, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced record total quarterly revenues of $1.82 million for the first quarter ended March 31, 2014, up 13 percent from the first quarter of 2013 and up sequentially 4 percent from the fourth quarter of 2013. The Company's core prenatal microarray test volumes in the first quarter of 2014 grew 60 percent to a record of 737 tests from 461 tests in the first quarter of 2013. Prenatal microarray revenue in the first quarter of 2014 was up 34 percent to a record $1.1 million from $836,000 in the first quarter of 2013. The Company also reported that its customer base continued to grow, reaching record levels of 150 customers for the first quarter of 2014, compared to 119 customers in the first quarter of 2013.
Help employers find you! Check out all the jobs and post your resume.
